EMA Endorses Two ADHD Treatments for Children 🔗 Access full article via Medscape NeurologyPaxneury and Tuzulby should be granted Europe-wide marketing authorizations for treating attention-deficit hyperactivity, the medicines regulator said. Medscape Medical News Share:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
